Search Results

The Japanese multinational pharma is pledging up to $580 million in a development and commercialization deal with AcuraStem for the latter’s PIKFYVE program for amyotrophic lateral sclerosis.

AcuraStem announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis, frontotemporal dementia, and other neurodegenerative diseases, announced that it has successfully raised nearly $7 million in grant funding for ALS / FTD research from the National Institutes of Health and the Department of Defense.

AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients.

AcuraStem (www.acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced today that Robert P. Bowser, Ph.D., Professor and Chair of Neurobiology at the Barrow Neurological Institute

One of the compounds in a series under development by AcuraStem for ALS, was administered to a neuronal cell line derived from a patient with CMT2A, and showed improved cell survival resulting in the identification as a promising new, preclinical drug candidate for CMT2A.

The Muscular Dystrophy Association has awarded an MDA Venture Philanthropy (MVP) grant totaling $300,000 over two years to AcuraStem Incorporated to support preclinical development of a novel small molecule therapeutic for amyotrophic lateral sclerosis (ALS).

The award from CDMRP will help fund the investigational new drug enabling toxicology studies for the company’s PIKFYVE-targeting drug candidate for ALS